• About Us
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Client Portal
  • Contact Us
  • today headline
  • Write for us
Today Headline
No Result
View All Result
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
No Result
View All Result
TodayHeadline
No Result
View All Result

Merck’s COVID-19 Pill May Be Less Effective Than First Hoped

November 30, 2021
in Health News
Reading Time: 3 mins read
1800x1200 lab research covid19 10 other - TodayHeadline


Nov. 29, 2021 — Merck’s antiviral pill for COVID-19, molnupiravir, appears to be far less effective than early results from the clinical trial first suggested.

According to an analysis by scientists at the FDA, the experimental pill cut the risk of hospitalization or death from COVID-19 by about 30%, compared to a placebo, and the pill showed no benefit for people with antibodies against COVID-19 from prior infection.

The updated analysis showed 48 hospitalizations or deaths among study participants who were randomly assigned to take the antiviral drug, compared to 68 among those who took a placebo.

Those results come from the full set of 1,433 patients who were randomized in the clinical trial, which just became available last week.

Initial results from the first 775 patients enrolled in the clinical trial, which were issued in a company news release in October, had said the drug cut the risk of hospitalization or death for patients at high risk of severe disease by about 50%.

Merck has been producing millions of doses of molnupiravir, which is the first antiviral pill to treat COVID-19 infections. The United Kingdom’s drug regulator authorized use of the medication in early November. The company said it expected to distribute the medication globally by the end of 2021.

Last month, two Indian drug companies halted late-stage clinical trials of a generic version of molnupiravir after the studies failed to find any benefit to patients with moderate COVID-19. Trials in patients with milder symptoms are still ongoing.

On Saturday, TheNew England Journal of Medicine postponed its planned early release of the molnupiravir study results, citing “new information.”

The medication is designed to be given as four pills taken every 12 hours for 5 days. It’s most effective when taken within the first few days of new symptoms, something that requires convenient and affordable testing.

The new results seem to put molnupiravir far below the effectiveness of existing treatments.

The infused monoclonal antibody cocktail REGEN-COV, which the FDA has already authorized for emergency use, is about 85% effective at preventing hospitalization or death in patients who are at risk for severe COVID-19 outcomes, and it appears to be just as effective in people who already have antibodies against COVID-19, which is why it is being given to both vaccinated and unvaccinated patients, the FDA said.

In early November, Pfizer said its experimental antiviral pill Paxlovid cut the risk of hospitalization or death by 89%.

In briefing documents posted ahead of an advisory committee meeting on Tuesday, the FDA highlights other potential safety issues with the Merck drug, which works by causing the virus to make mistakes as it copies itself, eventually causing the virus to mutate itself to death.

The agency has asked the advisory committee to weigh in on the right patient population for the drug: Should pregnant women get it? Could the drug harm a developing fetus?

Should vaccinated people with breakthrough infections get it? Would it work for them? People with reduced immune function are more likely to get a breakthrough infection. They’re also more likely to shed virus for a longer period of time, making them perfect incubators for variants. What could happen if we give this type of patient a drug that increases mutations?

And what about mutations caused by the medication? Could they increase the potential for more variants? The agency concluded the risk of this happening was low.

In animal studies, the drug impacted bone formation. For this reason, the agency has agreed with the drug company that molnupiravir should not be given to anyone under the age of 18.

Aside from these concerns, the FDA says there were no major safety issues among people who took part in the clinical trial, though they acknowledge that number is small.

  • Trending
  • Comments
  • Latest
Jeremy Renner reveals plan for new show once he039s 039back - TodayHeadline

Jeremy Renner reveals plan for new show once he's 'back on my feet' after horror accident

1675525436 social - TodayHeadline

I’m 66 and have $47,000 left in my 30-year mortgage. I’ll be 90 when it’s paid off. Should I refinance to a 15-year fixed?

20230203 fo tasting notes bill addison chef owner ryan wong needle silver lake pork belly char siu bun cover - TodayHeadline

The custard-filled French toast of your dreams is Cantonese

1024 aHR0cHM6Ly9zMy5jb2ludGVsZWdyYXBoLmNvbS9zdG9yYWdlL3VwbG9hZHMvdmlldy83NWEzZjhiOGMyZDNiYjQ1ODk3YWQxMzFjZTNhZDU4NS5qcGc - TodayHeadline

How to protect against crime in the metaverse

PopularStories

Jeremy Renner reveals plan for new show once he039s 039back - TodayHeadline
Lifestyle

Jeremy Renner reveals plan for new show once he's 'back on my feet' after horror accident

1675525436 social - TodayHeadline
Business news

I’m 66 and have $47,000 left in my 30-year mortgage. I’ll be 90 when it’s paid off. Should I refinance to a 15-year fixed?

20230203 fo tasting notes bill addison chef owner ryan wong needle silver lake pork belly char siu bun cover - TodayHeadline
Technology News

The custard-filled French toast of your dreams is Cantonese

1024 aHR0cHM6Ly9zMy5jb2ludGVsZWdyYXBoLmNvbS9zdG9yYWdlL3VwbG9hZHMvdmlldy83NWEzZjhiOGMyZDNiYjQ1ODk3YWQxMzFjZTNhZDU4NS5qcGc - TodayHeadline
Money

How to protect against crime in the metaverse

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

Jeremy Renner reveals plan for new show once he039s 039back - TodayHeadline

Jeremy Renner reveals plan for new show once he's 'back on my feet' after horror accident

1675525436 social - TodayHeadline

I’m 66 and have $47,000 left in my 30-year mortgage. I’ll be 90 when it’s paid off. Should I refinance to a 15-year fixed?

20230203 fo tasting notes bill addison chef owner ryan wong needle silver lake pork belly char siu bun cover - TodayHeadline

The custard-filled French toast of your dreams is Cantonese

Jeremy Renner reveals plan for new show once he039s 039back - TodayHeadline

Jeremy Renner reveals plan for new show once he's 'back on my feet' after horror accident

1675525436 social - TodayHeadline

I’m 66 and have $47,000 left in my 30-year mortgage. I’ll be 90 when it’s paid off. Should I refinance to a 15-year fixed?

20230203 fo tasting notes bill addison chef owner ryan wong needle silver lake pork belly char siu bun cover - TodayHeadline

The custard-filled French toast of your dreams is Cantonese

  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

No Result
View All Result
  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.